Life Extension Foundation Inc.

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 2 drugs with upcoming expirations

Activity

Key Events

Sep 25, 2023FDAOraverse — RYZUMVI

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

3 patent groups across drugs · Source: FDA Orange Book

DrugExpires

ClozarilMay 1, 2028 Oraverse6 patentsJan 31, 2034 Oraverse5 patentsOct 25, 2039

Regulatory

Regulatory Timeline

19821 event

FDAJan 1

Oraverse — REGITINE

Application NDA008278 (NDA)

19891 event

FDASep 26

Clozaril — CLOZARIL

Application NDA019758 (NDA)

20071 event

FDAMay 30

Clozaril — FAZACLO ODT

Application NDA021590 (NDA)

20081 event

FDAMay 9

Oraverse — ORAVERSE

Application NDA022159 (NDA)

20131 event

FDAFeb 6

Clozaril — VERSACLOZ

Application NDA203479 (NDA)

20231 event

FDASep 25

Oraverse — RYZUMVI

Application NDA217064 (NDA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)